Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, Allan P, Carey MS, Fernandez ML, Dawson A, Köbel M, Huntsman DG, Le Page C, Mes-Masson AM, Provencher D, Hacker N, Gao Y, Bowtell D, deFazio A, Gorringe KL, Campbell IG. Cheasley D, et al. Among authors: hunter s. J Pathol. 2021 Jan;253(1):41-54. doi: 10.1002/path.5545. Epub 2020 Oct 28. J Pathol. 2021. PMID: 32901952
Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM, Anglesio MS, Sharma R, Gilks CB, Melnyk N, Chiew YE, deFazio A; Australian Ovarian Cancer Study Group; Longacre TA, Huntsman DG, Gorringe KL, Campbell IG. Hunter SM, et al. Clin Cancer Res. 2011 Dec 1;17(23):7273-82. doi: 10.1158/1078-0432.CCR-11-2080. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976534
Genomic aberrations of BRCA1-mutated fallopian tube carcinomas.
Hunter SM, Ryland GL, Moss P; kConFab Investigators; Gorringe KL, Campbell IG. Hunter SM, et al. Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13. Am J Pathol. 2014. PMID: 24726640
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group; Gorringe KL, Campbell IG. Hunter SM, et al. Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438. Oncotarget. 2015. PMID: 26506417 Free PMC article.
The molecular origin and taxonomy of mucinous ovarian carcinoma.
Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL. Cheasley D, et al. Among authors: hunter sm. Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x. Nat Commun. 2019. PMID: 31477716 Free PMC article.
Therapeutic options for mucinous ovarian carcinoma.
Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL. Gorringe KL, et al. Among authors: hunter sm. Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2. Gynecol Oncol. 2020. PMID: 31902686 Free PMC article.
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators. Kang EY, et al. Mod Pathol. 2021 Jan;34(1):194-206. doi: 10.1038/s41379-020-0618-9. Epub 2020 Jul 28. Mod Pathol. 2021. PMID: 32724153 Free PMC article.
2,247 results